top of page
gradientForSurfBreak.png

Item List

Business Wire
Endeavor BioMedicines Partners with xCures

Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor's clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile. The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial. The xCures platform also enables patients to find more suitable treatment options if they are ineligible.

Recent Posts

Portfolio Company

Carlsmed.png

Regard and Kettering Health Hamilton Partner to Streamline EHR Navigation ...

PR Newswire

Portfolio Company

Carlsmed.png

Elektra Health Adds $3.3M in Seed Funding to Grow Its Platform for Evidence-base ...

FemTech Insider

Portfolio Company

Carlsmed.png

DeepScribe Launches New and Innovative Trust and Safety Suite for its Ambient AI ...

AIThority

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page